ClinicalTrials.gg
Not yet recruitingNCT07381244Updated Oct 30, 2026

Validity, Reliability, and Clinical Correlates of Immersive Virtual Reality Adaptation of the Five Times Sit-to-stand Test and Timed up and go Tests in Women With Fibromyalgia Syndrome

An observational study in Fibromyalgia Syndrome, sponsored by Selcuk University. Not yet recruiting. Open to female participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Selcuk University · Observational

How we know

Updated Oct 30, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
51
Ages
30 Years to 60 Years
Sex
Female
01

Study summary

Fibromyalgia syndrome (FMS) is a chronic rheumatic condition characterized by widespread pain, fatigue, and functional impairments that negatively affect physical activity levels, muscle strength, balance, and functional mobility. These impairments may lead to reduced functional capacity and increased sedentary behavior. Therefore, objective assessment of mobility, balance, and functional performance is essential in individuals with FMS.

Performance-based tests such as the Five Times Sit-to-Stand Test (5xSTS) and the Timed Up and Go (TUG) test are commonly used to evaluate lower extremity muscle function, balance, and functional mobility due to their simplicity, feasibility, and clinical relevance. Recently, virtual reality (VR)-based assessment methods have emerged as a standardized and objective approach for evaluating functional performance.

This study aims to investigate the feasibility and measurement properties of virtual reality-based adaptations of the 5xSTS and TUG tests in individuals with fibromyalgia syndrome using a head-mounted VR system. Findings from this study are expected to contribute to the clinical use of VR technology in mobility and balance assessment in individuals with FMS.

02

Conditions studied

  • Fibromyalgia Syndrome

Browse trials for

Keywords

  • Validity, reliability
  • fibromyalgia syndrome
  • virtual reality
03

In context

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

This study's planned enrollment of 51 is below the median of 100 across 280 observational studies indexed under Fibromyalgia.

Browse Fibromyalgia studies →

Lead sponsor

Selcuk University is the lead sponsor of 261 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will include adult individuals diagnosed with fibromyalgia according to established diagnostic criteria. Participants will be recruited from outpatient clinics and through announcements. All participants will be able to walk independently and will voluntarily agree to participate in the study. Demographic and clinical characteristics, physical performance, muscle strength, balance, physical activity level, and pain severity will be assessed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Having been diagnosed with FMS according to the American Rheumatology Association (ARB) 1990 classification criteria,

      • Being female between the ages of 30-60
      • Having the cognitive ability to understand the instructions
      • Being a volunteer

Exclusion criteria

Exclusion Criteria:

    • Severe physical disability

      • Rheumatological/neurological diseases
      • Any musculoskeletal problem (fracture, deformity, sprain)
      • Severe cognitive impairment
      • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
51 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Performans evaluation

    Performance outcomes will be assessed using the Five Times Sit-to-Stand Test (5xSTS) and the Timed Up and Go (TUG) test. These tests are widely used functional performance measures with established validity and reliability. In this study, virtual reality (VR) adaptations of both tests will also be applied. Participants will enter the testing environment using a VR headset, and test protocols will be conducted in the same manner as the conventional applications. The VR-based assessments will follow standardized procedures equivalent to the traditional versions of the 5xSTS and TUG tests.

    Time frame: Baseline and 7 days later (test-retest interval).

Secondary outcomes

  1. Hand Grip Strength

    Hand grip strength will be measured in a seated position following standardized testing posture, with the shoulder adducted and in neutral rotation, the elbow flexed to 90 degrees, the forearm supported in mid-rotation, and the wrist in a neutral position. Measurements will be obtained from the dominant hand using a handheld dynamometer. Participants will be instructed to perform a maximal voluntary contraction. Three trials will be conducted with 15-second rest intervals, and the highest value will be recorded in kilograms (kg).

    Time frame: Baseline

  2. Knee extension muscle strength

    Knee extension muscle strength will be measured using a handheld dynamometer in a seated position with the hip and knee flexed to 90 degrees. The lower legs will hang freely, and the arms will be crossed over the chest. The dynamometer will be positioned perpendicular to the leg, 1-2 cm proximal to the malleoli, with stabilization applied at the thigh. Three measurements will be obtained, and the highest value will be recorded in kilograms (kg)

    Time frame: baseline

  3. Physical Activity Level

    Physical activity level will be assessed using the 7-item short form of the International Physical Activity Questionnaire. The questionnaire evaluates time spent sitting, walking, moderate-intensity activities, and vigorous-intensity activities during the previous 7 days. Duration (minutes) and frequency (days) of each activity will be recorded. Total physical activity score will be calculated by multiplying activity duration by the corresponding metabolic equivalent (MET) value and summing all activity scores. Physical activity levels will be classified as physically inactive (\<600 MET-min/week), minimally active (600-3000 MET-min/week), or active (\>3000 MET-min/week).

    Time frame: baseline

  4. Single-Leg Balance Test Time

    Balance will be assessed using the single-leg balance test under eyes-open and eyes-closed conditions. Participants will stand on the dominant leg with the arms crossed over the chest while the contralateral leg is lifted from the ground with the knee flexed to approximately 45 degrees. Timing will begin once the test position is achieved. The test will be terminated if the arms or the non-stance leg are used for support or when the maximum duration of 30 seconds is reached. Time will be recorded in seconds. Each condition will be repeated three times, and the best performance will be recorded. The same procedure will be applied to the nondominant leg

    Time frame: baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 81 non-industry observational studies under Fibromyalgia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 109. This study's planned 3 months is below that.

Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 8 and three quarters within 91.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Feb 2026 → Dec 2026, primary completion Jun 2026 → Mar 2027 and completion Jul 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Feb 2, 2026
StartEst.
Dec 15, 2026was Feb 2026
Primary completionEst.
Mar 30, 2027was Jun 2026
CompletionEst.
Jun 30, 2027was Jul 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 15, 2026→Dec 15, 2026
Oct 30, 2026
Primary completion
Jun 30, 2026→Mar 30, 2027
Oct 30, 2026
Study completion
Jul 30, 2026→Jun 30, 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Start date Feb 15, 2026→Dec 15, 2026
    Primary completion Jun 30, 2026→Mar 30, 2027
    Study completion Jul 30, 2026→Jun 30, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07381244
Lead sponsor
Selcuk University
Responsible party
Zehra KORKUT (Principal Investigator, Selcuk University) — Principal investigator
First posted
Feb 2, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion